# Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention

> **NCT04778787** · PHASE4 · COMPLETED · sponsor: **I.M. Sechenov First Moscow State Medical University** · enrollment: 370 (actual)

## Conditions studied

- Congestive Heart Failure

## Interventions

- **DRUG:** Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)

## Key facts

- **NCT ID:** NCT04778787
- **Lead sponsor:** I.M. Sechenov First Moscow State Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-01
- **Primary completion:** 2022-08-01
- **Final completion:** 2022-08-01
- **Target enrollment:** 370 (ACTUAL)
- **Last updated:** 2022-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04778787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04778787, "Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04778787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*